Background
==========

The acute coronary syndrome (ACS) spectrum includes patients with ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable angina. Percutaneous coronary intervention (PCI) has become one of the most important treatment modalities for ACS patients \[[@b1-medscimonit-24-9354]\]. In recent years, several studies reported that high-dose atorvastatin pretreatment improves cardiovascular outcomes after PCI in ACS patients. Mechanistic studies have suggested that the possible protective effects of high-dose atorvastatin pretreatment in ACS patients reduce inflammatory cascade and anti-thrombotic activity and enhances coronary atherosclerotic plaque stability \[[@b2-medscimonit-24-9354]--[@b4-medscimonit-24-9354]\].

However, the beneficial effects of intensive atorvastatin therapy are still controversial. Recently, several studies have reported that high-dose atorvastatin pretreatment improves clinical outcomes for ACS patients undergoing PCI. A few studies have found atorvastatin significantly reduced the risk of major adverse cardiovascular events (MACEs) at 30 days in ACS patients treated with PCI when given a loading dose \[[@b5-medscimonit-24-9354]--[@b8-medscimonit-24-9354]\]. However, other investigations have yielded conflicting results and raised doubts about the usefulness of high-dose (≥80 mg daily) atorvastatin before PCI \[[@b9-medscimonit-24-9354]--[@b11-medscimonit-24-9354]\]. Whether intensive treatment with atorvastatin is an effective way to reduce hard cardiovascular events among ACS patients remains unclear. To shed further light on this issue, we performed a meta-analysis based on the current literature to determine whether ACS patients undergoing PCI benefit from high-intensity atorvastatin therapy.

Material and Methods
====================

Search strategy
---------------

An extensive literature search was conducted in PubMed, Embase, Cochrane CENTRAL, and Web of Science databases up to May 2018 to identify randomized controlled trials (RCTs) comparing high-dose atorvastatin preloading with control (placebo or low-dose atorvastatin therapy) in ACS patients undergoing PCI. The following keywords were used in searching: "atorvastatin", "acute coronary syndrome", "percutaneous coronary intervention", or "PCI", and "randomized" and "randomly". Additionally, we checked the references of the selected articles to find additional eligible publications. The studies selected included only those published in English language.

Study selection
---------------

The inclusion criteria were: (1) the RCTs included a direct comparison of high-dose atorvastatin versus low-dose atorvastatin or placebo therapy in humans; (2) patients with ACS (ST-segment elevation myocardial infarction \[STEMI\], unstable angina pectoris, or non-ST-segment elevation myocardial infarction \[NSTEMI\]); (3) patients who were undergoing current therapy with atorvastatin; (4) the study reported information on MACEs, change in serum high-sensitivity C-reactive protein (hs-CRP), peak creatine kinase-myocardial band (CK-MB) level, and TIMI grade 3 after PCI; and elevated liver transaminases as the main safety endpoint; and 5) the follow-up time was at least 30 days. Exclusion criteria were: (1) ongoing studies; (2) no control studies; (3) duplicate reports without additional or updated data; and (4) studies lacking baseline or follow-up data.

Data extraction
---------------

Data were extracted independently by 2 authors and cross-checked to reach a consensus. The following variables were obtained from each article: first author, publication year, study regions, study design, total number of subjects, clinical presentation, atorvastatin intervention and control measures before PCI, follow-up duration, clinical endpoints, and definition of MACEs.

Quality assessment
------------------

Study quality for RCTs was evaluated using the Cochrane Collaboration's tool for assessing risk of bias \[[@b12-medscimonit-24-9354],[@b13-medscimonit-24-9354]\]. This tool includes questions related to random-sequence generation, allocation concealment, blinding of the participants and personnel, blinding of the outcome assessment, incomplete outcome data, selective reporting, and other biases. Each aspect can further be classified as low, high, or unclear risk.

Statistical analysis
--------------------

Statistical analyses were performed using Rev-Man5.3 software (Cochrane Collaboration, Copenhagen, Denmark) and STATA software, version 12.0 (STATA Corp., College Station, TX). The Cochrane χ^2^ test and the I^2^ test were used to evaluate heterogeneity among studies, with a threshold value of *P*\<0.10 being considered significant \[[@b14-medscimonit-24-9354]\]. A random effects model was used when heterogeneity was present. Sensitivity analysis was performed to evaluate the stability of the results. Publication bias was assessed by funnel plot and Egger's regression test. Results were considered statistically significant at *P*\<0.05. All *P*-values are 2-tailed.

Results
=======

Selected studies and baseline characteristics
---------------------------------------------

The flow diagram of the study analysis is shown in [Figure 1](#f1-medscimonit-24-9354){ref-type="fig"}. Of 397 potentially relevant articles initially screened, 17 RCTs \[[@b3-medscimonit-24-9354],[@b5-medscimonit-24-9354]--[@b11-medscimonit-24-9354],[@b15-medscimonit-24-9354]--[@b23-medscimonit-24-9354]\] met the inclusion criteria and were included in the final meta-analysis consisting of a total of 10 072 ACS patients, of which 5024 were randomized to the high-dose atorvastatin group and 5048 were randomized to the control group. The clinical characteristics of patients included in the meta-analysis are reported in [Table 1](#t1-medscimonit-24-9354){ref-type="table"}. All studies were published in English.

Risk of bias in included studies
--------------------------------

Judgments on each risk of bias item for all studies are shown in [Figures 2](#f2-medscimonit-24-9354){ref-type="fig"} and [3](#f3-medscimonit-24-9354){ref-type="fig"}. Most of the included trials had a potential risk of allocation concealment, selective reporting, and other biases. Due to the small number of eligible studies, none were excluded.

Effect of high-dose atorvastatin preloading on short-term MACEs in ACS patients undergoing PCI
----------------------------------------------------------------------------------------------

Nine trials \[[@b5-medscimonit-24-9354]--[@b11-medscimonit-24-9354],[@b18-medscimonit-24-9354],[@b22-medscimonit-24-9354]\] evaluated the effects of high-dose atorvastatin pretreatment on the incidence of MACEs in ACS patients who had PCI. The overall pooled results of the random-effects model showed that high-dose atorvastatin therapy led to a 28% relative reduction in MACEs compared with the control medical therapy (OR=0.72, 95% CI: 0.56 to 0.94, P=0.01; I^2^=51%, P~het~=0.04; [Figure 4](#f4-medscimonit-24-9354){ref-type="fig"}).

Effect of high-dose atorvastatin preloading on hs-CRP level in ACS patients undergoing PCI
------------------------------------------------------------------------------------------

The effects of high-dose atorvastatin pretreatment on hs-CRP level were also analyzed in 9 trials \[[@b3-medscimonit-24-9354],[@b6-medscimonit-24-9354]--[@b9-medscimonit-24-9354],[@b15-medscimonit-24-9354],[@b16-medscimonit-24-9354],[@b18-medscimonit-24-9354],[@b21-medscimonit-24-9354]\]. Overall, high-dose atorvastatin reduced serum hs-CRP level in ACS patients after PCI (SMD −1.59; 95% CI: −2.38 to −0.80; *P*\<0.0001), and statistical heterogeneity was evident among these studies (P\<0.00001, I^2^=97%; [Figure 5](#f5-medscimonit-24-9354){ref-type="fig"}).

Effect of high-dose atorvastatin preloading on peak CK-MB and final TIMI flow grade in ACS patients undergoing PCI
------------------------------------------------------------------------------------------------------------------

According to [Figure 3C](#f3-medscimonit-24-9354){ref-type="fig"}, there were 6 studies \[[@b7-medscimonit-24-9354],[@b9-medscimonit-24-9354],[@b17-medscimonit-24-9354]--[@b20-medscimonit-24-9354]\] used for the quantitative analysis of the level of peak CK-MB in ACS patients after PCI (SMD −0.34; 95% CI: −0.79 to 0.10, P=0.13; I^2^=84%, P~het~\<0.00001; [Figure 6](#f6-medscimonit-24-9354){ref-type="fig"}). Regarding the final TIMI flow grade 3 after PCI, the pooling analysis also showed that high-dose atorvastatin did not provide an additional benefit in post-procedural TIMI flow grade 3 (OR=1.31, 95% CI: 0.73 to 2.36, P=0.36; I^2^=0%, P~het~=0.54; [Figure 7](#f7-medscimonit-24-9354){ref-type="fig"}).

Effect of high-dose atorvastatin preloading on serum alanine aminotransferase level
-----------------------------------------------------------------------------------

Four studies \[[@b5-medscimonit-24-9354],[@b8-medscimonit-24-9354],[@b17-medscimonit-24-9354],[@b18-medscimonit-24-9354]\] evaluated whether high-dose atorvastatin treatment increased serum ALT. No significant differences were observed in terms of elevated liver ALT between high-dose atorvastatin therapy and the control group (OR=1.95, 95% CI: 0.95 to 4.03, P=0.07; I^2^=48%, P~het~=0.12; [Figure 8](#f8-medscimonit-24-9354){ref-type="fig"}).

Sensitivity analysis
--------------------

Sensitivity analysis was performed for the hs-CRP level data with high heterogeneity. After removing each study, sensitivity analysis showed similar results (data not shown). Sensitivity analysis confirmed the stability of our results.

Publication bias diagnostics
----------------------------

The result of the funnel plot suggested that no publication bias was present based on the MACEs results ([Figure 9](#f9-medscimonit-24-9354){ref-type="fig"}), which was also statistically supported by Begg's test (p=0.119) and Egger's test (p= 0.125).

Discussion
==========

This meta-analysis of 10 072 individuals from 17 RCTs shows that high-dose atorvastatin pretreatment significantly reduced the incidence of short-term MACEs and lowered hs-CRP levels in ACS patients after PCI. However, high-dose atorvastatin pretreatment did not improve TIMI myocardial perfusion grade or an additional reduction in peak CK-MB in ACS patients after PCI. In addition, high-dose atorvastatin pretreatment did not increase the risk of hepatotoxicity compared to the placebo/low-dose atorvastatin group.

In recent years, several studies reported that high-dose atorvastatin pretreatment improves cardiovascular outcomes after PCI in ACS patients. However, the beneficial effects of intensive atorvastatin therapy are still controversial. In some studies, such as those by Kim \[[@b9-medscimonit-24-9354]\] and Jang \[[@b10-medscimonit-24-9354]\], high-dose atorvastatin pretreatment before PCI did not show a significant reduction of MACEs compared with low-dose atorvastatin, but other studies, such as those by Patti \[[@b6-medscimonit-24-9354]\], Sun \[[@b7-medscimonit-24-9354]\], and Liu \[[@b8-medscimonit-24-9354]\] found that ACS patients benefit from high-dose atorvastatin preloading before PCI. Recently, Berwanger et al. \[[@b11-medscimonit-24-9354]\] found that high-dose atorvastatin pretreatment in patients with ACS did not reduce the rate of MACEs at 30 days. Considering these conflicting conclusions, a meta-analysis was required to confirm the efficacy and safety of high-dose atorvastatin treatment in ACS patients.

ACS is a complex disorder that encompasses tissue remodeling, necrosis, and thrombosis, and persistent inflammatory processes contribute to the aggravation of atherosclerosis and ACS \[[@b24-medscimonit-24-9354]\]. hs-CRP is an acute-phase protein synthesized by the liver and is closely related with inflammation. It is reported that serum hs-CRP level can be a postoperative factor to predict future events in ACS patients \[[@b25-medscimonit-24-9354]\]. As a consequence, intensive atorvastatin treatment during acute myocardial infarction could reduce clinical events by anti-inflammatory effects. In contrast to previous findings \[[@b18-medscimonit-24-9354],[@b26-medscimonit-24-9354]\], our results show that the possible reason is mainly due to the distal coronary microembolization and high thrombotic burden associated with ACS.

The present meta-analysis has several features that distinguish it from a similar meta-analysis \[[@b27-medscimonit-24-9354]\]. First, the prior meta-analysis, by Liu et al., was based on 9 RCTs and enrolled 3 studies published in Chinese, so the quality of the articles may not be as high as studies published in English journals. To limit bias in the selection of included studies, we only included RCTs published in English. Second, although our meta-analysis yielded a similar overall reduction in the incidence of MACEs, we included 2 additional RCTs. Third, this meta-analysis found that high-dose atorvastatin reduced hs-CRP level after PCI, but post-PCI TIMI 3 flow was not improved.

The present study is one of the largest systematic reviews of the literature that used meta-analysis to study whether high-dose atorvastatin pretreatment before PCI improves clinical endpoints in ACS patients undergoing PCI. This study has certain limitations. Firstly, different doses and durations of atorvastatin treatment in ACS patients from different regions may have various effects on clinical outcomes. Secondly, most included trials were not long enough. Hence, more RCTs with high quality and longer follow-up periods are required to identify the beneficial cardiac effects of atorvastatin preloading before PCI. Thirdly, MACEs were not uniformly defined. Therefore, reporting bias is possible in our study.

Conclusions
===========

Our meta-analysis demonstrates that high-dose atorvastatin pretreatment can reduce the rate of short-term MACEs and hs-CRP levels without increasing drug-induced hepatotoxicity in ACS patients after PCI. Larger additional RCTs with larger sample sizes and longer follow-up periods are needed to confirm the clinical benefits of high-dose atorvastatin loading in ACS patients who undergo primary PCI.

**Source of support:** Departmental sources
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###### 

Details of included studies and extracted statistics used in the meta-analysis.

  Study              Study design (trials)          Location                     Clinical feature              Loading dose and timing before PCI                                                          Patients number statin loading/control   Outcomes                                                            Definition of the MACEs                                                                                                                                                                                                   The main results of study
  ------------------ ------------------------------ ---------------------------- ----------------------------- ------------------------------------------------------------------------------------------- ---------------------------------------- ------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Schwartz (2001)    RCT (MIRACL)                   International multi-center   Unstable angina or NSTE-ACS   Atorvastatin 80 mg/day before PCI *vs.* placebo pretreatment                                1538/1548                                MACEs at 16 weeks                                                   Death, non-fatal acute MI, cardiac arrest with resuscitation, or recurrent symptomatic myocardial ischemia with objective evidence and requiring emergency re-hospitalization                                             Atorvastatin 80 mg/day significantly reduced the risk of recurrent ischemic events
  Patti (2007)       RCT (ARMYDA-ACS)               Multi-center in Italy        NSTE-ACS                      Atorvastatin 80 mg then 40 mg/day before PCI *vs.* placebo pretreatment                     86/85                                    MACEs at 30 days                                                    Death, MI, target vessel revascularization                                                                                                                                                                                High-dose atorvastatin pretreatment conferred an 88% risk reduction of 30-day major adverse cardiac events by multivariable analysis
  Ordulu (2008)      RCT                            Turkey                       Unstable angina or NSTE-ACS   Atorvastatin 80 mg/day before PCI *vs.* placebo pretreatment                                20/20                                    Post-PCI hs-CRP level                                               --                                                                                                                                                                                                                        High-dose atorvastatin pretreatment significantly reduced hs-CRP levels
  Zhao (2009)        RCT                            China                        Unstable angina               Atorvastatin 80 mg/day before PCI *vs.* 20 mg atorvastatin pretreatment                     85/79                                    Post-PCI hs-CRP level                                               --                                                                                                                                                                                                                        80 mg/day atorvastatin therapy significantly reduced the levels of inflammatory factors (hs-CRP, IL-6 and TNF-α), improved vascular endothelial function compared with the 20 mg mg/day atorvastatin-treated group
  Kim (2010)         RCT (The STATIN STEMI trial)   Multi-center in Korea        STEMI                         Atorvastatin 80 mg/day before PCI *vs.* 10 mg atorvastatin pretreatment                     86/85                                    MACEs at 30 days, hs-CRP level, peak CK-MB, Final TIMI flow grade   Death, non-fatal MI, and target vessel revascularization                                                                                                                                                                  High-dose atorvastatin pretreatment before PCI did not show a significant reduction of MACEs compared with low-dose atorvastatin but did show improved immediate coronary flow after primary PCI
  Sun (2010)         RCT                            China                        NSTE-ACS                      Atorvastatin 80 mg then 60 mg/day before PCI *vs.* 40 mg atorvastatin pretreatment          20/20                                    MACEs at 30 days, hs-CRP level, peak CK-MB                          Cardiac death, MI and revascularization treatment                                                                                                                                                                         High-dose pre-PCI atorvastatin therapy reduced the incidence of MACEs, the post-PCI hs-CRP and CK-MB levels
  Hahn (2011)        RCT                            Multi-center in Korea        STEMI                         Atorvastatin 80 mg/day before PCI *vs.* 10 mg atorvastatin pretreatment                     89/84                                    Final TIMI flow grade, ALT elevation                                --                                                                                                                                                                                                                        High-dose atorvastatin pretreatment before PCI did not reduce infarct size measured by SPECT
  Yu (2011)          RCT                            China                        NSTE-ACS                      Atorvastatin 80 mg then 40 mg/day before PCI *vs.* placebo pretreatment                     41/40                                    MACEs at 30 days, hs-CRP level, peak CK-MB, ALT elevation           Cardiac death, MI and target vessel revascularization                                                                                                                                                                     High-dose atorvastatin pretreatment before PCI reduced the incidence of MACEs, the post-PCI hs-CRP and CK-MB levels
  Post (2012)        RCT                            Netherlands                  STEMI                         Atorvastatin 80 mg/day before PCI *vs.* placebo pretreatment                                20/22                                    Peak CK-MB level and Final TIMI flow grade after PCI                --                                                                                                                                                                                                                        High-dose atorvastatin pretreatment before PCI did not result in an improved cardiac function, microvascular perfusion, or decreased myocardial infarct size
  Liu HL (2013)      RCT                            China                        STEMI                         Atorvastatin 80 mg/day before PCI *vs.* placebo pretreatment                                32/32                                    Peak CK-MB level and Final TIMI flow grade after PCI                --                                                                                                                                                                                                                        High-dose atorvastatin pretreatment before PCI reduced the levels of inflammatory factors (hs-CRP, BNP and MMP-9), and improved cardiac function
  Jang (2014)        RCT (ALP-ACS)                  Korea and China              NSTE-ACS                      Atorvastatin 80 mg then 40 mg/day before PCI *vs.* 40 mg atorvastatin pretreatment          247/252                                  MACEs at 30 days                                                    Death, MI, and target vessel revascularization                                                                                                                                                                            High-dose atorvastatin pretreatment before PCI did not reduce the incidence of MACEs and with higher LV systolic function
  Shehata (2015)     RCT                            Egypt                        NSTE-ACS                      Atorvastatin 80 mg/day before PCI *vs.* 10 mg atorvastatin pretreatment                     58/60                                    hs-CRP level and Final TIMI flow grade                              --                                                                                                                                                                                                                        High-dose atorvastatin pretreatment before PCI was associated with better biochemical outcome in terms of lower hs-CRP and LDL-C levels after PCI and with higher left ventricular systolic function
  Yang (2015)        RCT                            China                        Unstable angina               Atorvastatin 80 mg/day before PCI *vs.* 20 mg atorvastatin pretreatment                     48/48                                    Final TIMI flow grade                                               --                                                                                                                                                                                                                        High-dose atorvastatin pretreatment before PCI reduced the inflammatory response in monocytes via PPARγ activation
  Liu Z (2016)       RCT (CLEAN)                    China                        ACS                           Atorvastatin 80 mg before PCI then 40 mg thereafter *vs.* 20 mg atorvastatin pretreatment   276/280                                  MACEs at 30 days, hs-CRP level, ALT elevation                       Cardiovascular death, spontaneous MI, and unplanned revascularization                                                                                                                                                     High-dose atorvastatin pretreatment before PCI reduced the incidence of MACEs
  Gavazzi (2017)     RCT                            Italy                        STEMI                         Atorvastatin 80 mg/day before PCI *vs.* 20 mg atorvastatin pretreatment                     26/26                                    hs-CRP level                                                        --                                                                                                                                                                                                                        High-dose atorvastatin pretreatment before PCI improved endothelial function and vascular inflammation
  Periti (2017)      RCT                            India                        STEMI                         Atorvastatin 80 mg/day before PCI *vs.* 10 mg atorvastatin pretreatment                     512/515                                  MACEs at 30 days                                                    Death from any cause, myocardial infarction, documented NSTE-ACS requiring readmission, ischemia driven revascularization with either percutaneous coronary intervention or coronary-artery bypass grafting, and stroke   High-dose atorvastatin pretreatment before PCI did not reduce the incidence of MACEs, but showed significant improvement in immediate coronary flow depicted by ST-segment resolution
  Berwanger (2018)   RCT (SECURE-PCI)               Multi-center in Brazil       ACS                           Atorvastatin 80 mg/day before PCI *vs.* placebo pretreatment                                2087/2104                                MACEs at 30 days                                                    All-cause mortality, acute MI, stroke, and unplanned coronary revascularization                                                                                                                                           High-dose atorvastatin pretreatment before PCI did not reduce the incidence of MACEs

RCT -- randomized controlled trial; NSTE-ACS -- non-ST-elevation acute coronary syndrome; STEMI -- ST-elevation myocardial infarction; PCI -- percutaneous coronary intervention; MACEs -- major adverse cardiac events; hs-CRP -- high-sensitivity C-reactive protein; CK-MB -- creatine kinase-myocardial band; TIMI -- thrombolysis in myocardial infarction; MI -- myocardial infarction; SPECT -- single-photon emission computed tomography.
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